Multidisciplinary Rehabilitation for Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease: a Case Report
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an inflammatory central nervous system disease that is driven by antibodies of the immunoglobulin G1 class. MOGAD has recently been recognized as an autoimmune disease; therefore, little is known about its rehabilitation. Here, we present a case of MOGAD that showed significant recovery after rehabilitation. A 58-year-old woman developed weakness in all extremities, dysarthria, and dysphagia. She visited the neurology department, and early brain and spine magnetic resonance imaging showed multifocal high intensity in the subcortical and periventricular white matter and the cervical cord. The patient's serum tested positive for anti-MOG antibodies. She was diagnosed with MOGAD and received intravenous steroid pulse therapy. After pharmacologic therapy, the patient was transferred to the rehabilitation department. Initially, her Functional Independence Measure (FIM) motor score was 26, allowing her to stand independently for only a few seconds. After 5 weeks of rehabilitation involving physical therapy, occupational therapy, and balance training, her FIM motor score improved to 60. However, 4 months after discharge, the disease relapsed with symptoms of motor weakness in all extremities, and steroid treatment was initiated. On the second admission, her FIM motor score was 42, but after continuous multidisciplinary rehabilitation, it improved to 76. Computerized cognitive therapy improved her cognitive function, from a Korean version of the Mini-Mental State Examination score of 23 on the first admission to 30 on final discharge. Since MOGAD is a relapsing disease, a favorable outcome can be achieved with continuous monitoring and multidisciplinary, symptom-specific rehabilitation.
Abstract
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an inflammatory central nervous system disease that is driven by antibodies of the immunoglobulin G1 class. MOGAD has recently been recognized as an autoimmune disease; therefore, little is known about its rehabilitation. Here, we present a case of MOGAD that showed significant recovery after rehabilitation. A 58-year-old woman developed weakness in all extremities, dysarthria, and dysphagia. She visited the neurology department, and early brain and spine magnetic resonance imaging showed multifocal high intensity in the subcortical and periventricular white matter and the cervical cord. The patient's serum tested positive for anti-MOG antibodies. She was diagnosed with MOGAD and received intravenous steroid pulse therapy. After pharmacologic therapy, the patient was transferred to the rehabilitation department. Initially, her Functional Independence Measure (FIM) motor score was 26, allowing her to stand independently for only a few seconds. After 5 weeks of rehabilitation involving physical therapy, occupational therapy, and balance training, her FIM motor score improved to 60. However, 4 months after discharge, the disease relapsed with symptoms of motor weakness in all extremities, and steroid treatment was initiated. On the second admission, her FIM motor score was 42, but after continuous multidisciplinary rehabilitation, it improved to 76. Computerized cognitive therapy improved her cognitive function, from a Korean version of the Mini-Mental State Examination score of 23 on the first admission to 30 on final discharge. Since MOGAD is a relapsing disease, a favorable outcome can be achieved with continuous monitoring and multidisciplinary, symptom-specific rehabilitation.
참고문헌 (23)
- KroepflJF, "Investigation of myelin", oligodendrocyte glycoprotein membrane topology, 1996, pp.67, 2219~2222
- Brilot F, "Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease", Ann Neurol, 66, pp.833~842 (2009)
- Chen JJ, "Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis : clinical characteristics, radiologic clues, and outcome", Am J Ophthalmol, 195, pp.8~15 (2018)
- Reindl M, "Myelin oligodendrocyte glycoprotein antibodies in neurological disease", Nat Rev Neurol, 15, pp.89~102 (2019)
- Narayan R, "MOG antibody disease : a review of MOG antibody seropositive neuromyelitis optica spectrum disorder", Mult Scler Relat Disord, 25, pp.66~72 (2018)
- López-Chiriboga AS, "Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders", JAMA Neurol, 75, pp.1355~1363 (2018)
- Jurynczyk M, "Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis", Brain, 140, pp.617~627 (2017)
- Netravathi M, "Myelin oligodendrocyte glycoprotein-antibody-associated disorder : a new inflammatory CNS demyelinating disorder", J Neurol, 268, pp.1419~1433 (2021)
- Latimer-Cheung AE, "Effects of exercise training on fitness, mobility, fatigue, and health-related quality of life among adults with multiple sclerosis : a systematic review to inform guideline development", Arch Phys Med Rehabil, 94, pp.1800~1828 (2013)
- Khan F, "Multidisciplinary rehabilitation for adults with multiple sclerosis", Cochrane Database Syst Rev, pp.CD006036~ (2007)
- Bonavita S, "Computer-aided cognitive rehabilitation improves cognitive performances and induces brain functional connectivity changes in relapsing remitting multiple sclerosis patients : an exploratory study", J Neurol, 262, pp.91~100 (2015)
- Latimer-Cheung AE, "Development of evidence-informed physical activity guidelines for adults with multiple sclerosis", Arch Phys Med Rehabil, 94, pp.1829~1836 (2013)
- Ciotti JR, "Clinical and laboratory features distinguishing MOG antibody disease from multiple sclerosis and AQP4 antibody-positive neuromyelitis optica", Mult Scler Relat Disord, 45, pp.102399~ (2020)
- Tajfirouz DA, "Clinical characteristics and treatment of MOG-IgG–associated optic neuritis", Curr Neurol Neurosci Rep, 19, pp.100~ (2019)
- Weber MS, "Defining distinct features of anti-MOG antibody associated central nervous system demyelination", Ther Adv Neurol Disorder, 11, pp.1756286418762083~ (2018)
- Healy S, "Treatment of myelin oligodendrocyte glycoprotein immunoglobulin G–associated disease", Clin Exp Neuroimmunol, 12, pp.22~41 (2021)
- Goldenberg MM, "Multiple sclerosis review", P&T, 37, pp.175~184 (2012)
- Langer-Gould A, "Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis : a systematic review", Arch Neurol, 63, pp.1686~1691 (2006)
- "Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): clinical features and diagnosis"[URL]
- Dubey D, "Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody", JAMA Neurol, 76, pp.301~309 (2019)
- Hirst CL, "Temporal evolution of remission following multiple sclerosis relapse and predictors of outcome", Mult Scler, 18, pp.1152~1158 (2012)
- Craig J, "A randomised controlled trial comparing rehabilitation against standard therapy in multiple sclerosis patients receiving intravenous steroid treatment", J Neurol Neurosurg Psychiatry, 74, pp.1225~1230 (2003)
- Jurynczyk M, "Clinical presentation and prognosis in MOG-antibody disease : a UK study", Brain, 140, pp.3128~3138 (2017)